{"id":323676,"date":"2026-10-22T12:35:05","date_gmt":"2026-10-22T07:05:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=323676"},"modified":"2026-10-22T12:35:05","modified_gmt":"2026-10-22T07:05:05","slug":"oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/","title":{"rendered":"3 Oncology and Biologics, Formulation Outsourcing and Eye and Skin Care Brands Stocks With a Strong Future Roadmap: Shilpa Medicare, Innova Captab and Ajanta Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Shilpa Medicare, Innova Captab and Ajanta Pharma: ROE of 9.4% to 23.3% and FY22 to FY26 revenue CAGR of 7.5% to 19.5%. Prices as of 21 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three oncology and contract pharma stocks to watch are Shilpa Medicare, Innova Captab and Ajanta Pharma. Their return on equity ranges from 9.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.5%. Ajanta Pharma has the highest return on equity at 23.3%, while Innova Captab has the fastest revenue growth at 19.5% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Oncology and contract pharma stocks let investors follow companies that make cancer medicines, manufacture for others and build niche brands. Shilpa Medicare, Innova Captab and Ajanta Pharma cover oncology and biologics, formulation outsourcing, and eye and skin care brands.<\/p>\n<p>This list covers three oncology and contract pharma stocks with complete current figures: Shilpa Medicare, Innova Captab and Ajanta Pharma. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#What_Are_Oncology_and_Contract_Pharma_Stocks\" title=\"What Are Oncology and Contract Pharma Stocks?\">What Are Oncology and Contract Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Oncology_and_Contract_Pharma_Stocks_at_a_Glance\" title=\"Oncology and Contract Pharma Stocks at a Glance\">Oncology and Contract Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Why_Do_Oncology_and_Contract_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Oncology and Contract Pharma Stocks Have a Strong Roadmap in India?\">Why Do Oncology and Contract Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Why_Shilpa_Medicare_Features_Among_These_Oncology_and_Contract_Pharma_Stocks\" title=\"Why Shilpa Medicare Features Among These Oncology and Contract Pharma Stocks\">Why Shilpa Medicare Features Among These Oncology and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Why_Innova_Captab_Features_Among_These_Oncology_and_Contract_Pharma_Stocks\" title=\"Why Innova Captab Features Among These Oncology and Contract Pharma Stocks\">Why Innova Captab Features Among These Oncology and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Why_Ajanta_Pharma_Features_Among_These_Oncology_and_Contract_Pharma_Stocks\" title=\"Why Ajanta Pharma Features Among These Oncology and Contract Pharma Stocks\">Why Ajanta Pharma Features Among These Oncology and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Shilpa_Medicare_vs_Innova_Captab_vs_Ajanta_Pharma_on_Key_Financials\" title=\"Shilpa Medicare vs Innova Captab vs Ajanta Pharma on Key Financials\">Shilpa Medicare vs Innova Captab vs Ajanta Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Key_Risks_to_Check_Before_Investing_in_Oncology_and_Contract_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Oncology and Contract Pharma Stocks\">Key Risks to Check Before Investing in Oncology and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Final_Thoughts_on_Oncology_and_Contract_Pharma_Stocks\" title=\"Final Thoughts on Oncology and Contract Pharma Stocks\">Final Thoughts on Oncology and Contract Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#What_are_oncology_and_contract_pharma_stocks\" title=\"What are oncology and contract pharma stocks?\">What are oncology and contract pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Which_oncology_and_contract_pharma_stocks_are_covered_in_this_list\" title=\"Which oncology and contract pharma stocks are covered in this list?\">Which oncology and contract pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Why_do_oncology_and_contract_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do oncology and contract pharma stocks have a strong future roadmap in India?\">Why do oncology and contract pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#How_has_Shilpa_Medicare_performed_financially\" title=\"How has Shilpa Medicare performed financially?\">How has Shilpa Medicare performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#How_has_Innova_Captab_performed_financially\" title=\"How has Innova Captab performed financially?\">How has Innova Captab performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#How_has_Ajanta_Pharma_performed_financially\" title=\"How has Ajanta Pharma performed financially?\">How has Ajanta Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#What_risks_should_investors_check_before_buying_oncology_and_contract_pharma_stocks\" title=\"What risks should investors check before buying oncology and contract pharma stocks?\">What risks should investors check before buying oncology and contract pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands-stocks-roadmap-outpost-list\/#Is_this_list_of_oncology_and_contract_pharma_stocks_investment_advice\" title=\"Is this list of oncology and contract pharma stocks investment advice?\">Is this list of oncology and contract pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Oncology_and_Contract_Pharma_Stocks\"><\/span><strong>What Are Oncology and Contract Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oncology and contract pharma stocks are listed pharmaceutical companies that focus on cancer care, make formulations for other drug marketers or sell niche branded generics. Their earnings depend on approvals, customer contracts and brand strength.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Oncology_and_Contract_Pharma_Stocks_at_a_Glance\"><\/span><strong>Oncology and Contract Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/shilpamed\/shilpa-medicare-ltd-share-price-today\">Shilpa Medicare<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">845.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17,132<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">57.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.25<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/innovacap\/innova-captab-ltd-share-price-today\">Innova Captab<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">980.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,736<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.32<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,260.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">41,241<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E above their industry P\/E, which reflects the growth the market already expects from them. Readers comparing oncology and contract pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in oncology and contract pharma stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Oncology_and_Contract_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Oncology and Contract Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oncology and contract pharma stocks have a strong roadmap in India because cancer care is a growing category, drug marketers are outsourcing production and niche brands build loyal prescription bases.<\/p>\n<ul>\n<li><strong>Cancer care demand.<\/strong> More diagnosis and treatment lifts demand for oncology medicines.<\/li>\n<li><strong>Outsourced production.<\/strong> Marketers use partners to make formulations at scale.<\/li>\n<li><strong>Niche brands.<\/strong> Eye and skin care brands win repeat prescriptions.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Shilpa_Medicare_Features_Among_These_Oncology_and_Contract_Pharma_Stocks\"><\/span><strong>Why Shilpa Medicare Features Among These Oncology and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the oncology and contract pharma stocks on this list, Shilpa Medicare, headquartered in Raichur, Karnataka, is a pharmaceutical company with active ingredients, formulations, biologics and contract development and manufacturing under one roof, with a focus on oncology.<\/p>\n<p>The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P\/E of 57.6, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.<\/p>\n<p><strong>What to watch:<\/strong> Follow regulatory approvals and commercial launches, since these drive the timing of earnings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Innova_Captab_Features_Among_These_Oncology_and_Contract_Pharma_Stocks\"><\/span><strong>Why Innova Captab Features Among These Oncology and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the formulation outsourcing shares on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.<\/p>\n<p>Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.<\/p>\n<p><strong>What to watch:<\/strong> Watch the growth in the branded business and the utilisation of expanded capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ajanta_Pharma_Features_Among_These_Oncology_and_Contract_Pharma_Stocks\"><\/span><strong>Why Ajanta Pharma Features Among These Oncology and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.<\/p>\n<p>In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.<\/p>\n<p>Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shilpa_Medicare_vs_Innova_Captab_vs_Ajanta_Pharma_on_Key_Financials\"><\/span><strong>Shilpa Medicare vs Innova Captab vs Ajanta Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three oncology and contract pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Shilpa Medicare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,160<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,549<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">243<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Innova Captab<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">803<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,637<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">141<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,457<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,625<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,056<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ajanta Pharma posts the highest return on equity in this group at 23.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with oncology and contract pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Shilpa Medicare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">328<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">469<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">43.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Innova Captab<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">473<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,329<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,697<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Oncology_and_Contract_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Oncology and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these oncology and contract pharma stocks, the main points are: Long-term formulation outsourcing shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Customer concentration.<\/strong> A few large customers can shape contract revenue.<\/li>\n<li><strong>Approval timelines.<\/strong> Launches depend on regulatory decisions that can shift.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter oncology and contract pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Oncology_and_Contract_Pharma_Stocks\"><\/span><strong>Final Thoughts on Oncology and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oncology and contract pharma stocks reward investors who follow approvals, customer contracts and brand growth together. Shilpa Medicare, Innova Captab and Ajanta Pharma each target a distinct niche. Based on the 21 October 2026 close, Shilpa Medicare trades at Rs 845.2, Innova Captab at Rs 980.2 and Ajanta Pharma at Rs 3,260.2. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these oncology and contract pharma stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track oncology and contract pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_oncology_and_contract_pharma_stocks\"><\/span><strong>What are oncology and contract pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Oncology and contract pharma stocks are listed pharmaceutical companies that focus on cancer care, make formulations for other drug marketers or sell niche branded generics. Their earnings depend on approvals, customer contracts and brand strength. This list looks at three of them, Shilpa Medicare, Innova Captab and Ajanta Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_oncology_and_contract_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which oncology and contract pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Shilpa Medicare, Innova Captab and Ajanta Pharma. Based on the 21 October 2026 close, Shilpa Medicare traded at Rs 845.2, Innova Captab at Rs 980.2 and Ajanta Pharma at Rs 3,260.2. Their return on equity ranges from 9.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.5%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_oncology_and_contract_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do oncology and contract pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Oncology and contract pharma stocks have a strong roadmap in India because cancer care is a growing category, drug marketers are outsourcing production and niche brands build loyal prescription bases. The main drivers are as follows. Cancer care demand. More diagnosis and treatment lifts demand for oncology medicines. Outsourced production. Marketers use partners to make formulations at scale. Niche brands. Eye and skin care brands win repeat prescriptions. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Shilpa_Medicare_performed_financially\"><\/span><strong>How has Shilpa Medicare performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P\/E of 57.6, above the industry P\/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Innova_Captab_performed_financially\"><\/span><strong>How has Innova Captab performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ajanta_Pharma_performed_financially\"><\/span><strong>How has Ajanta Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_oncology_and_contract_pharma_stocks\"><\/span><strong>What risks should investors check before buying oncology and contract pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying oncology and contract pharma stocks. Customer concentration. A few large customers can shape contract revenue. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_oncology_and_contract_pharma_stocks_investment_advice\"><\/span><strong>Is this list of oncology and contract pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are oncology and contract pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oncology and contract pharma stocks are listed pharmaceutical companies that focus on cancer care, make formulations for other drug marketers or sell niche branded generics. Their earnings depend on approvals, customer contracts and brand strength. This list looks at three of them, Shilpa Medicare, Innova Captab and Ajanta Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which oncology and contract pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Shilpa Medicare, Innova Captab and Ajanta Pharma. Based on the 21 October 2026 close, Shilpa Medicare traded at Rs 845.2, Innova Captab at Rs 980.2 and Ajanta Pharma at Rs 3,260.2. Their return on equity ranges from 9.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.5%.\"}},{\"@type\":\"Question\",\"name\":\"Why do oncology and contract pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oncology and contract pharma stocks have a strong roadmap in India because cancer care is a growing category, drug marketers are outsourcing production and niche brands build loyal prescription bases. The main drivers are as follows. Cancer care demand. More diagnosis and treatment lifts demand for oncology medicines. Outsourced production. Marketers use partners to make formulations at scale. Niche brands. Eye and skin care brands win repeat prescriptions. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Shilpa Medicare performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P\/E of 57.6, above the industry P\/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.\"}},{\"@type\":\"Question\",\"name\":\"How has Innova Captab performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.\"}},{\"@type\":\"Question\",\"name\":\"How has Ajanta Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying oncology and contract pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying oncology and contract pharma stocks. Customer concentration. A few large customers can shape contract revenue. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of oncology and contract pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oncology and Contract Pharma Stocks with a strong future roadmap: Shilpa Medicare, Innova Captab and Ajanta Pharma. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.<\/p>\n","protected":false},"author":36,"featured_media":323674,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[13959,3803,14737,5864,14736,14738,7424],"class_list":["post-323676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-ajanta-pharma","tag-best-stocks","tag-formulation-outsourcing-shares","tag-innova-captab","tag-oncology-and-contract-pharma-stocks","tag-ophthalmology-and-dermatology-brand-stocks","tag-shilpa-medicare"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["323674"],"rank_math_title":["Oncology and Contract Pharma Stocks With a Strong Roadmap"],"rank_math_description":["Compare 3 oncology and contract pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 21 Oct 2026."],"rank_math_focus_keyword":["oncology and contract pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-oncology-and-biologics-formulation-outsourcing-and-eye-and-skin-care-brands.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=323676"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323676\/revisions"}],"predecessor-version":[{"id":323677,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323676\/revisions\/323677"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/323674"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=323676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=323676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=323676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}